Stock Price Quote

GUFIC BIOSCIENCES LTD.

NSE : GUFICBIOBSE : 509079ISIN CODE : INE742B01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE318.703.45 (+1.09 %)
PREV CLOSE ( ) 315.25
OPEN PRICE ( ) 315.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10354
TODAY'S LOW / HIGH ( )314.60 322.85
52 WK LOW / HIGH ( )192 364
NSE320.756.3 (+2 %)
PREV CLOSE( ) 314.45
OPEN PRICE ( ) 315.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 320.75 (2)
VOLUME 78750
TODAY'S LOW / HIGH( ) 314.10 323.45
52 WK LOW / HIGH ( )193.55 364.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-07 1984
Management Info
Jayesh P Choksi - Chairman Jayesh P Choksi - Managing Director
Registered Office

Address Shop - 37, First Floor,Kamala Bhavan I I,Swami Nityanand Road, Andheri East,
Mumbai,
Maharashtra-400069

Phone

Email info@guficbio.com

Website www.guficbio.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

04Apr Gufic Biosciences incorporates Wholly
Gufic Biosciences has incorporated a Wholly Owned Subsidiary Company in..
02Apr Gufic Biosciences informs about demise
Gufic Biosciences has informed about the sad demise of Shrirang Vaidya (..
09Jan Gufic Biosciences informs about compli
Gufic Biosciences has informed that it enclosed certificate received fro..
23Nov Gufic Biosciences informs about transc
In continuation to communication dated November 17, 2023 on Earnings Con..
20Nov Gufic Biosciences incorporates subsidi
Gufic Biosciences has incorporated a subsidiary Company in India namely..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit222.57797.05
Gross Profit 295.58 1067.21
Operating Profit 368.791372.25
Net Sales 2017.786906.21

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6217.15 (4.47%)
M.Cap ( in Cr)103713.42
Abbott India (BSE)
peergroup  25725.00 (1.03%)
M.Cap ( in Cr)54663.83
Bharat Parenterals (BSE)
peergroup  1701.80 (10.00%)
M.Cap ( in Cr)990.39
Alkem Laboratories (BSE)
peergroup  4857.90 (3.10%)
M.Cap ( in Cr)58083.48
NGL Fine-Chem (BSE)
peergroup  2711.85 (3.47%)
M.Cap ( in Cr)1675.39

Shareholding Pattern

PROMOTERS 72.51%
NON-INSTITUTION 25.18%
MUTUAL FUNDS/UTI 2.08%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Gufic Biosciences Ltd.

Gufic Biosciences Ltd. was incorporated in the year 1984. Its today's share price is 318.7. Its current market capitalisation stands at Rs 3195.84 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8008.26 Cr and Total Income of Rs.6931.95 Cr. The company's management includes Ami Shah, Balram Singh, Rabi N Sahoo, Shreyas K Patel, Anu S Aurora, Gopal Daptari, Dilip B Ghosh, Pankaj J Gandhi, Pranav J Choksi, Jayesh P Choksi, Jayesh P Choksi.

It is listed on the BSE with a BSE Code of 509079 , NSE with an NSE Symbol of GUFICBIO and ISIN of INE742B01025. It's Registered office is at Shop - 37, First Floor,Kamala Bhavan I I,Swami Nityanand Road, Andheri EastMumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Mayur Chokshi & Co, Mittal Agarwal & Co, SHR & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.